These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11385711)

  • 1. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript.
    Vega A; Campos B; Bressac-De-Paillerets B; Bond PM; Janin N; Douglas FS; Domènech M; Baena M; Pericay C; Alonso C; Carracedo A; Baiget M; Diez O
    Hum Mutat; 2001 Jun; 17(6):520-1. PubMed ID: 11385711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
    Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
    Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
    Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
    Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
    Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
    Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin.
    Santos C; Peixoto A; Rocha P; Vega A; Soares MJ; Cerveira N; Bizarro S; Pinheiro M; Pereira D; Rodrigues H; Castro F; Henrique R; Teixeira MR
    Fam Cancer; 2009; 8(3):203-8. PubMed ID: 19123044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Odefrey F; Domènech M; Moncoutier V; Martínez-Ferrandis JI; Osorio A; Balmaña J; Barroso A; Armengod ME; Benítez J; Alonso C; Stoppa-Lyonnet D; Goldgar D; Baiget M
    Hum Mutat; 2003 Apr; 21(4):452. PubMed ID: 12655574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
    Southey MC; Tesoriero A; Young MA; Holloway AJ; Jenkins MA; Whitty J; Misfud S; kConFab ; McLachlan SA; Venter DJ; Armes JE
    Hum Mutat; 2003 Jul; 22(1):86-91. PubMed ID: 12815598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?
    Russo A; Calò V; Bruno L; Schirò V; Agnese V; Cascio S; Foddai E; Fanale D; Rizzo S; Di Gaudio F; Gulotta E; Surmacz E; Di Fede G; Bazan V
    Breast Cancer Res Treat; 2009 Jan; 113(1):67-70. PubMed ID: 18228134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent origin of 185delAG BRCA1 mutation in an Indian family.
    Kadalmani K; Deepa S; Bagavathi S; Anishetty S; Thangaraj K; Gajalakshmi P
    Neoplasma; 2007; 54(1):51-6. PubMed ID: 17203892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels.
    Zhang L; Chen L; Bacares R; Ruggeri JM; Somar J; Kemel Y; Stadler ZK; Offit K
    Breast Cancer Res Treat; 2011 Dec; 130(3):1051-6. PubMed ID: 21863257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts.
    Gutiérrez-Enríquez S; Coderch V; Masas M; Balmaña J; Diez O
    Breast Cancer Res Treat; 2009 Sep; 117(2):461-5. PubMed ID: 18712473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
    Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
    Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model.
    Yang Y; Swaminathan S; Martin BK; Sharan SK
    Hum Mol Genet; 2003 Sep; 12(17):2121-31. PubMed ID: 12915465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding.
    Millevoi S; Bernat S; Telly D; Fouque F; Gladieff L; Favre G; Vagner S; Toulas C
    Breast Cancer Res Treat; 2010 Apr; 120(2):391-9. PubMed ID: 19404736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
    Hadjisavvas A; Charalambous E; Adamou A; Neuhausen SL; Christodoulou CG; Kyriacou K
    Cancer Genet Cytogenet; 2004 Jun; 151(2):152-6. PubMed ID: 15172753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.